Mr. Claudio Solitario
- Life-Saving Innovation: AI-based intellectual property for the fast and early identification of life threatening pulmonary embolisms using CAT scan detection software. A pulmonary embolism is a medical emergency; it may be fatal causing death. Pulmonary embolism affects around 900,000 people in the U.S. every year[1]. The AI-powered technology aims to improve the radiologic processing time and reading performance during emergency evaluations.
- Facial Analysis to objectively screen for PTSD: AI-based facial analysis technology to objectively screen for post-traumatic stress disorder. The technology will analyze and interpret facial data, the result of which will be seen immediately by the user – with an option of sending it to their medical practitioner. This innovative approach will empower individuals and their healthcare providers to proactively manage mental health. The incidence of mental illness in the USA is well known; and the cost is estimated at $300Billion annually[2]. A quick and objective assessment of PTSD is required by patients and healthcare professionals alike.
- Evolution in Evaluation and Treatment of Pain Management: A breakthrough new AI program (Chatbot) to simulate conversation with individuals suffering from chronic pain. The program will be designed to immediately address the pain sufferer’s acute and chronic pain and provide viable options to consider as they search for a medical personnel who has the appropriate expertise. It will also create a written dialogue that can be reviewed by medical practitioners and may become an integral part of the pain sufferer’s comprehensive pain management plan. This breakthrough AI-based technology, under the guidance of Dr. Robert Lawrence, a retired Neurologist with PhDs in Nuclear Physics and Biomedical Engineering, along with MS Degrees in Computer Science and Pharmacology, will be a game-changer for the over 51 million Americans (over 20% of the adult population[3]) affected by chronic pain.
"We are excited to embark on this transformative journey. AI is fast becoming an important tool in the quest for faster and more accurate diagnoses. Our mission is to leverage AI to enhance health outcomes and reduce healthcare costs. We also look forward to launching our pioneering anti-anxiety formula, the first of our nutraceutical products. The market demand for nutraceuticals is significant and growing, representing an early revenue opportunity for the Company. The path ahead is exciting and we look forward to keeping shareholders abreast of progress in the coming weeks and months".
Mr. Claudio Solitario, CEO
PRISM MediaWire - Maximizing Impact. Reaching Millions